<DOC>
	<DOCNO>NCT02109146</DOCNO>
	<brief_summary>1 . Hepatocellular carcinoma ( HCC ) common primary malignancy liver , represent third leading cause cancer-related death worldwide . 2 . Its overall dismal prognosis result high incidence rate metastasis postoperative recurrence , particular intrahepatic recurrence . 3 . TACE widely use primary treatment unresectable HCC . It also use optional treatment relapse disease . However , efficacy TACE use adjuvant therapy follow hepatectomy remain controversial .</brief_summary>
	<brief_title>Postoperative TACE ( Transhepatic Arterial Chemotherapy And Embolization ) Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Pathological diagnosis HCC ( AJCC stage I II ) Without recurrence 1 month postoperation Must tolerant TACE With intrahepatic recurrence postoperation Insufficient liver function Stage III IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TACE</keyword>
	<keyword>Postoperation</keyword>
</DOC>